Tom 8, Nr 2 (2023)
Praca badawcza (oryginalna)
Opublikowany online: 2023-04-27

dostęp otwarty

Wyświetlenia strony 1718
Wyświetlenia/pobrania artykułu 91
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Evaluation of the incidence of splenic hilar lymph node metastasis in patients operated on for esophagogastric junction cancer

Tomasz Olesiński1, Marek Szpakowski1, Wojciech Każmierczak1, Urszula Sulkowska2, Andrzej Rutkowski1
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2023;8(2):92-96.

Streszczenie

Introduction.The purpose of this study is to evaluate the effect of esophagogastric junction cancer (EGJC) staging on the risk of splenic hilar lymph node involvement.

Material and methods.312 patients with EGJC after R0 surgery were analyzed; 118 (38%) women and 194 (62%) men, median age 58 (29–80) years. In 81 (25.27%) cases, metastases were found in splenic lymph nodes (gr. 10).

Results.in stage I and II A (IA and IB), no metastases were found in splenic hilar lymph nodes (0/42 and 0/18, respectively), in stage IIB 9.61% (5/52), in IIIA 21.74% (15/69), in IIIB 36.36% (16/44), in IIIC 46.83% (37/79), and in stage IV 100% (8/8).

Conclusions.The highest risk of metastasis of esophagogastric junction cancer to splenic hilar lymph nodes exists in caners stage III and IV. Spleen-sparing elective splenectomy or group 10 lymphadenectomy may be of importance in the treatment of patients with stage III and IV gastroesophageal junction cancer, however, the assessment of its usefulness requires further prospective clinical trials.

Artykuł dostępny w formacie PDF

Pokaż PDF (angielski) Pobierz plik PDF

Referencje

  1. Kasakura Y, Fujii M, Mochizuki F, et al. Is there a benefit of pancreaticosplenectomy with gastrectomy for advanced gastric cancer? Am J Surg. 2000; 179(3): 237–242.
  2. Sasako M. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br J Surg. 1997; 84(11): 1567–1571.
  3. Degiuli M, Sasako M, Ponzetto A, et al. Extended lymph node dissection for gastric cancer: results of a prospective, multi-centre analysis of morbidity and mortality in 118 consecutive cases. Eur J Surg Oncol. 1997; 23(4): 310–314.
  4. Hansson LE, Ekström AM, Bergström R, et al. Surgery for stomach cancer in a defined Swedish population: current practices and operative results. Swedish Gastric Cancer Study Group. Eur J Surg. 2000; 166(10): 787–795.
  5. Yasuda K, Shiraishi N, Adachi Y, et al. Risk factors for complications following resection of large gastric cancer. Br J Surg. 2001; 88(6): 873–877.
  6. Chikara K, Hiroshi S, Masato N, et al. Indications for pancreaticosplenectomy in advanced gastric cancer. Hepatogastroenterology. 2001; 48(39): 908–912.
  7. Csendes A, Burdiles P, Rojas J, et al. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery. 2002; 131(4): 401–407.
  8. Schmid A, Thybusch A, Kremer B, et al. Differential effects of radical D2-lymphadenectomy and splenectomy in surgically treated gastric cancer patients. Hepatogastroenterology. 2000; 47(32): 579–585.
  9. Takahashi M, Fujimoto S, Kobayashi K, et al. Indication for splenectomy combined with total gastrectomy for gastric cancer: analisis of data on 249 gastric cancer patients. Hepatogastroenterology. 1995; 42(3): 230–233.
  10. Griffith JP, Sue-Ling HM, Martin I, et al. Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut. 1995; 36(5): 684–690.
  11. Sano T, Sasako M, Mizusawa J, et al. Stomach Cancer Study Group of the Japan Clinical Oncology Group. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg. 2017; 265(2): 277–283.
  12. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021; 24(1): 1–21.
  13. Pierzankowski I, Dmitruk A, Rybski S, et al. The influence of surgery quality on the longtime results of gastric cancer combination therapy. Nowotwory. Journal of Oncology. 2022; 72(4): 219–225.
  14. Lo SS, Wu CW, Shen KH, et al. Higher morbidity and mortality after combined total gastrectomy and pancreaticosplenectomy for gastric cancer. World J Surg. 2002; 26(6): 678–682.
  15. Budisin N, Budisin E, Golubovic A. Early complications following total gastrectomy for gastric cancer. J Surg Oncol. 2001; 77(1): 35–41.
  16. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996; 347(9007): 995–999.
  17. Ding P, Gao Z, Zheng C, et al. Risk evaluation of splenic hilar or splenic artery lymph node metastasis and survival analysis for patients with proximal gastric cancer after curative gastrectomy: a retrospective study. BMC Cancer. 2019; 19(1): 905.
  18. Zhong Q, Chen QY, Xu YC, et al. Reappraise role of No. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: a pooled analysis of 4 prospective trial. Gastric Cancer. 2021; 24(1): 245–257.
  19. Son T, Kwon InG, Lee JHo, et al. Impact of splenic hilar lymph node metastasis on prognosis in patients with advanced gastric cancer. Oncotarget. 2017; 8(48): 84515–84528.
  20. Zheng G, Liu J, Guo Y, et al. Necessity of prophylactic splenic hilum lymph node clearance for middle and upper third gastric cancer: a network meta-analysis. BMC Cancer. 2020; 20(1): 149.
  21. Lin JX, Wang ZK, Huang YQ, et al. Clinical Relevance of Splenic Hilar Lymph Node Dissection for Proximal Gastric Cancer: A Propensity Score-Matching Case-Control Study. Ann Surg Oncol. 2021; 28(11): 6649–6662.
  22. Du J, Shen Y, Yan W, et al. Risk factors of lymph node metastasis in the splenic hilum of gastric cancer patients: a meta-analysis. World J Surg Oncol. 2020; 18(1): 233.
  23. Liu K, Chen XZ, Zhang YC, et al. The value of spleen-preserving lymphadenectomy in total gastrectomy for gastric and esophagogastric junctional adenocarcinomas: A long-term retrospective propensity score match study from a high-volume institution in China. Surgery. 2021; 169(2): 426–435.
  24. Bencivenga M, Torroni L, Verlato G, et al. Lymphadenectomy for gastric cancer at European specialist centres. Eur J Surg Oncol. 2021; 47(5): 1048–1054.
  25. Kinoshita T, Okayama T. Is splenic hilar lymph node dissection necessary for proximal gastric cancer surgery? Ann Gastroenterol Surg. 2021; 5(2): 173–182.
  26. Bonenkamp JJ, Hermans J, Sasako M, et al. Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999; 340(12): 908–914.
  27. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006; 7(4): 309–315.
  28. Sasako M, Sano T, Yamamoto S, et al. Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008; 359(5): 453–462.
  29. Peeters KC, Hundahl SA, Kranenbarg EK, et al. Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial. World J Surg. 2005; 29(12): 1576–1584.
  30. Hundahl SA. Low Maruyama Index Surgery for Gastric Cancer. Scand J Surg. 2016; 95(4): 243–248.



Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory